BBI, some thoughts on your post in no particular order. I don't think any of us understand the Generics' reasoning for entering the market so stupidly early. Only thing I can think of (and it really I don't think makes much sense) is that there were many that were anxious to get into selling GV and had there only been one Generic interested in doing so, maybe they would have waited.
Otherwise you do make a good point about the other Generics not being named in the suit. However, I am not sure if that might be because the legal angle has taken a twist from what was previously planned. What I mean by that is of course the idea well elucidated by Sleven and maybe others that our attorneys will attempt to follow the GSK-Teva playbook in terms of showing that there is no way craft a skinny label in this situation where it would not infringe. So if anyone can opine on your point of the other players not being named and this strategy and its effect, I would appreciate that.
Market Data 
Markets 
AI
